Mortality of Patients Infected by COVID-19 with and without Deep-Vein Thrombosis

Medicines (Basel). 2021 Nov 29;8(12):75. doi: 10.3390/medicines8120075.

Abstract

Background: Current evidence points to a state of hypercoagulability (consequence of hyperinflammation) as an important pathogenic mechanism that contributes to the increase in mortality in cases of COVID-19. The aim of the present study was to investigate the influence of deep-vein thrombosis on mortality patient's infected with SARS-CoV-2.

Method: A clinical trial was conducted involving 200 consecutive patients with COVID-19-100 patients who were positive for deep-vein thrombosis (venous Doppler ultrasound) and 100 who were negative for deep-vein thrombosis at a public hospital.

Results: The mortality rate was 67% in the group positive for DVT and 31% in the group negative for DVT.

Conclusion: Deep-vein thrombosis is associated with an increase in mortality in patients with COVID-19 and failures can occur with conventional prophylaxis for deep-vein thrombosis.

Keywords: COVID-19; Doppler; deep-vein thrombosis; mortality; ultrasound.